Fig. 8: ISV with FOLactis initiated antigen-specific therapeutic effect and inhibited multiple types of immunologically “cold” cancer.
a Schematic diagram of the therapeutic treatment in tumor-bearing mice. Mice were inoculated (s.c.) with tumor cells (5 × 105 per mouse), and received treatments on days 7, 9 and 11. Created with BioRender.com. Average tumor-growth curves (b), survival data (c) and body weight (d) of C57BL/6 mice bearing B16F10-OVA tumor with different treatments as indicated (n = 8). The dose of different treatments was the same as Fig. 4b. Tr: treated; NT: nontreated. e Generation of antigen-specific CD8+ T cell responses in tumors of B16F10-OVA-bearing mice (n = 3). Representative flow cytometry images of OVA+CD8+ T cells gated on CD3+ T cells two days after treatments and their flow cytometric analysis. f–h BALB/c mice were implanted with 4T1-GFP-Luc cells (2 × 105) on the left and right lower sides of the abdomen on day 0 or day 3, and received treatments on days 7, 9, and 11 (n = 6). Anterior bioluminescence images of tumor burden on days 7, 14, 21, and 28 after tumor inoculation (f). Shown are the tumor signal (g) and overall survival (h). i, j Immunohistochemistry analysis of CD8 or PD1 expression in 4T1-GFP-Luc treated tumors seven days after treatments (n = 3). Scale bars, Left, 200 µm; Right, 100 µm. For the experiments in b and g, data were the mean ± s.e.m. p-values were determined by two-way ANOVA with Tukey’s multiple comparisons test. ns represented p > 0.05. For the experiments in d and e, data were the mean ± s.e.m. p-values were determined by two-tailed unpaired Student’s t-tests. ns represented p > 0.05. Differences in survival were estimated by the Kaplan–Meier analysis, and the p value was determined via the log-rank (Mantel–Cox) test. Source data are provided as a Source Data file.
